By Kathryn Bryant Knudson, Founder
The Speak Foundation
Evolyra Therapeutics is a cutting-edge biotechnology company on a mission to bring life-changing treatments to people living with Limb-Girdle Muscular Dystrophy (LGMD). Based in Richmond, Virginia, the company is developing next-generation gene replacement therapies designed specifically for rare neuromuscular conditions that currently have no cures.
Founded by a team of physician-scientists and biotech leaders, Evolyra Therapeutics is working to change the future for individuals with LGMD type 2C and type 2D, two severe subtypes of the disease that cause progressive muscle weakness, loss of mobility, and serious impacts on quality of life. Their approach is rooted in a deep understanding of muscle biology, patient need, and the limitations of past therapies.
What makes Evolyra unique is its second-generation AAV vector platform—engineered to deliver a full-length, functional gene directly to muscle tissue, while avoiding toxicity in other organs like the liver. This improved design reflects lessons learned from earlier gene therapy trials and offers the potential for safer, more effective treatments.
Evolyra Therapeutics is also distinguished by its close partnership with the GRASP-LGMD Patient Consortium, a global network of clinicians, scientists, and patient advocates focused on accelerating research in LGMD. This collaboration gives Evolyra access to clinical trial-ready infrastructure, natural history data, and patient voices that help guide every stage of therapy development.
Still in preclinical stages, the company is preparing for future clinical trials in the next year while advancing its manufacturing and regulatory plans. Their ultimate goal is to deliver curative gene therapies—not just symptom management—for families who have long waited for meaningful options.
In a field where progress has often been slow and uncertain, Evolyra Therapeutics offers a fresh wave of hope for the LGMD community. With innovative science, a committed team, and a patient-centered approach, they are working to turn the tide in one of the most challenging areas of neuromuscular medicine.